Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth.
From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.
